Millan MJ - Search Results

1

Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.

Cussac D, Newman-Tancredi A, Nicolas JP, Boutin JA, Millan MJ. Cussac D, et al. Among authors: millan mj. Naunyn Schmiedebergs Arch Pharmacol. 2000 May;361(5):549-54. doi: 10.1007/s002100000221. Naunyn Schmiedebergs Arch Pharmacol. 2000. PMID: 10832610

2

Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.

Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Goldstein S, Millan MJ. Cussac D, et al. Among authors: millan mj. Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):242-52. doi: 10.1007/s00210-001-0505-y. Epub 2002 Jan 16. Naunyn Schmiedebergs Arch Pharmacol. 2002. PMID: 11882920

3

Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.

Cussac D, Duqueyroix D, Newman-Tancredi A, Millan MJ. Cussac D, et al. Among authors: millan mj. Psychopharmacology (Berl). 2002 Jul;162(2):168-77. doi: 10.1007/s00213-002-1043-0. Epub 2002 Apr 30. Psychopharmacology (Berl). 2002. PMID: 12110994

4

Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.

Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ. Cussac D, et al. Among authors: millan mj. Mol Pharmacol. 2002 Sep;62(3):578-89. doi: 10.1124/mol.62.3.578. Mol Pharmacol. 2002. PMID: 12181434

5

Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling.

Newman-Tancredi A, Cussac D, Marini L, Millan MJ. Newman-Tancredi A, et al. Among authors: millan mj. Mol Pharmacol. 2002 Sep;62(3):590-601. doi: 10.1124/mol.62.3.590. Mol Pharmacol. 2002. PMID: 12181435

6

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.

Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ. Newman-Tancredi A, et al. Among authors: millan mj. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. doi: 10.1124/jpet.102.039875. J Pharmacol Exp Ther. 2002. PMID: 12388667

7

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.

Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ. Newman-Tancredi A, et al. Among authors: millan mj. J Pharmacol Exp Ther. 2002 Nov;303(2):815-22. doi: 10.1124/jpet.102.039883. J Pharmacol Exp Ther. 2002. PMID: 12388668

8

Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine.

Cussac D, Pasteau V, Millan MJ. Cussac D, et al. Among authors: millan mj. Eur J Pharmacol. 2004 Feb 6;485(1-3):111-7. doi: 10.1016/j.ejphar.2003.11.077. Eur J Pharmacol. 2004. PMID: 14757130

9

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.

Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G. Millan MJ, et al. J Pharmacol Exp Ther. 2008 Feb;324(2):587-99. doi: 10.1124/jpet.107.126706. Epub 2007 Nov 16. J Pharmacol Exp Ther. 2008. PMID: 18024789

10

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G. Millan MJ, et al. J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16. J Pharmacol Exp Ther. 2012. PMID: 22178752

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

433 results

Search Page